Sharp Edge Labs: Discovering Drugs to Treat Genetic Disorders of Protein Trafficking.

Sharp Edge Labs
Sharp Edge LabsFriday, March 25th, 2016 at 10:15am
Sharp Edge Labs announces a drug discovery alliance with stem cell pioneer ORIG3N to bring patients into the earliest stages of the drug discovery process (well, patients' stem cells that is).
5 1    View on Facebook
Sharp Edge Labs
Sharp Edge Labs shared Alzheimer's Drug Discovery Foundation's post.Thursday, February 11th, 2016 at 10:49am
An important study showing that knowledge is power (power to change).
   View on Facebook
Sharp Edge Labs
Sharp Edge LabsFriday, February 5th, 2016 at 10:02am
Company Founder Marcel Bruchez just published a new work in Nature Methods in using the biosensor technology for targeted photosensitization in-vivo. Very cool stuff, and a whole new direction for the technology.
1    View on Facebook
1    View on Facebook
Sharp Edge Labs
Sharp Edge LabsMonday, February 1st, 2016 at 1:05am
Company founders Alan Waggoner and Marcel Bruchez are interviewed by the Pittsburgh Post Gazette on creating the technology that drives discovery at Sharp Edge Labs.
4    View on Facebook
Off the Shelf
  • Monogenic Diseases
    Caused by a single gene alteration, monogenic diseases represent an area of high unmet need, but also of great therapeutic opportunity.
  • Trafficking Defects
    Many monogenic diseases result from a mutation that causes improper trafficking, the failure of the mutated protein to get to the right place inside the cell.
  • Patient-Driven Discovery
    Stem-Cell technology allows patients to participate in drug discovery programs at their earliest stages.
On the Bench
Sharp Edge Radar